U.S. Hospitality Stock News

NasdaqGM:ARCT
NasdaqGM:ARCTBiotechs

Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?

Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking. This high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers. With this conference spotlight and recent share price...
NasdaqGS:MASI
NasdaqGS:MASIMedical Equipment

How Investors May Respond To Masimo (MASI) Record Hospital Contracts And Preliminary 2025 Revenue Growth

Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-year 2025 results indicating approximately 12% quarterly and 9% annual revenue growth. Management also highlighted a record level of incremental contract value from new and expanded hospital agreements, underscoring the importance of long-term customer relationships to the business. We’ll now examine how the record incremental...
OTCPK:HONT
OTCPK:HONTBanks

Honat Bancorp (OTCPK:HONT) Earnings Growth Outpaces Long Run Trend And Fuels Margin Expansion Narrative

Honat Bancorp (HONT) has put another solid quarter on the board, with Q2 2025 revenue of US$11.4 million and basic EPS of US$2.57 feeding into trailing twelve month EPS of US$10.46 on revenue of US$44.6 million and net income of US$15.0 million. Over the past year, the company has seen revenue move from US$38.8 million to US$44.6 million on a trailing basis, while EPS climbed from US$8.33 to US$10.46, and earnings growth of 19% has supported a net profit margin of 33.5% compared with 31.2% a...
NasdaqGM:CDNA
NasdaqGM:CDNABiotechs

Is It Time To Reassess CareDx (CDNA) After Recent Share Price Reset?

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...